Anti-Human Immunodeficiency Virus Drug Combination Strategies

Anne‐Mieke Vandamme; Kristien Van Vaerenbergh; De Clercq Erik

doi:10.1177/095632029800900301

Abstract

1 min read

It is now generally accepted that mono- and bitherapy for human immunodeficiency virus type 1 (HIV-1) infection are only transiently efficient mainly due to virus drug resistance. To obtain a sustained benefit from antiviral therapy, current guidelines recommend at least triple-drug combinations, or the so-called highly active antiretroviral therapy (HAART). In some patients, HAART can be problematic, either because it is difficult to remain compliant or because previous suboptimum therapies have limited the choice of drugs. For compliant drug-naive patients, HAART should be able to offer long-term virus suppression, when changing from first- to second- to third-line HAART at drug failure. Long-term treatment might ultimately result in multi-drug resistant virus leaving few options for salvage therapy. HIV drug resistance testing to guide this salvage therapy and the development of new drugs to allow new options will therefore remain priorities in anti-HIV drug research.

Related publications

Article2002

Initiation of HAART in Drug-Naive HIV Type 1 Patients Prevents Viral Breakthrough for a Median Period of 35.5 Months in 60% of the Patients

Kristien Van Vaerenbergh, Thomas Harrer, Jean‐Claude Schmit, An Carbonez, Elodie Fontaine, Michael Kurowski, Mathias Grünke, Peter Löw, Astrid Rascu, Bárbara Schmidt, Matthias Schmitt, Inge Thoelen, H Walter, Kristel Van Laethem, Marc Van Ranst, Jan Desmyter, De Clercq Erik, Anne‐Mieke Vandamme

Article2010

Blocking Nuclear Import of Pre-Integration Complex: An Emerging Anti-HIV-1 Drug Discovery Paradigm

Peng Zhan, Xinyong Liu, De Clercq Erik

Article2004

Novel Inhibitors of HIV-1 Integration

Myriam Witvrouw, Bénédicte Van Maele, Jo Vercammen, Anke Hantson, Yves Engelborghs, De Clercq Erik, Christophe Pannecouque, Zeger Debyser

Article2002

A Combination of Poor Adherence and a Low Baseline Susceptibility Score is Highly Predictive for HAART Failure

Kristien Van Vaerenbergh, Sabina De Geest, Inge Derdelinckx, Herman Bobbaers, An Carbonez, Ann Deschamps, Veerle De Graeve, Veerle De Saar, Helga Ceunen, Koen De Smet, Bart Maes, Willy Peetermans, Yoeri Schrooten, Jan Desmyter, De Clercq Erik, Marc Van Ranst, Eric Van Wijngaerden, Anne‐Mieke Vandamme

Article2023

Recommendations on data sharing in HIV drug resistance research

Seth Inzaule, Mark J. Siedner, Susan J. Little, Santiago Ávila‐Ríos, Alisen Ayitewala, Ronald J. Bosch, Vincent Cálvez, Francesca Ceccherini‐Silberstein, Charlotte Charpentier, Diane Descamps, Susan H. Eshleman, Joseph Fokam, Lisa M. Frenkel, Ravindra K. Gupta, John P A Ioannidis, Pontiano Kaleebu, Rami Kantor, Seble Kassaye, Sergei L. Kosakovsky Pond, Vinie Kouamou, Roger D. Kouyos, Daniel R. Kuritzkes, Richard Lessells, Anne‐Geneviève Marcelin,